Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VENITI, Inc.
After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.
Celltrion has struck a deal with 180 Life Sciences to supply anti-TNF products to support the company’s work in pursuing new indications for off-patent biologics.
The US FDA approval of Boston Scientific's Vici venous stent is based on VIRTUS trial results which met the prespecified performance goal for primary patency after one year.
Boston Scientific has agreed to pay up to $160m for the remaining 75% of Veniti Inc. that it does not already own. Veniti is a privately held Fremont, Calif. company that has developed and commercialized the Vici venous stent system for treating venous obstructive disease. The transaction price includes $108m upfront and $52m contingent on US FDA approval of Vici.